24/7 Market News Snapshot 31 March, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

March 31, 2025

DENVER, Colo., 31 March, 2025 (247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
bioAffinity Technologies, Inc. is making headlines with a remarkable surge in both share price and operational advancements. Recently, the company saw significant interest in its stock, opening at $0.27 and experiencing a staggering increase of nearly 186%, currently trading at $0.749. This enthusiastic market response is underpinned by heightened investor confidence in bioAffinity’s cutting-edge diagnostic technologies, particularly its noninvasive lung cancer test, CyPath® Lung.

Financially, bioAffinity has reported record revenues of $9.4 million for the year ending December 31, 2024, which represents an impressive 270% growth from the previous year. This surge can be attributed to a remarkable 1,400% increase in orders for CyPath® Lung, as healthcare professionals increasingly recognize the value of this diagnostic tool. The company’s commitment to advancing lung cancer detection is further enhanced by the recent establishment of a unique CPT code for CyPath® Lung by the Centers for Medicare and Medicaid Services, effective January 1, 2024. This development facilitates reimbursement opportunities, broadening access to this vital test across both Medicare and private insurance plans.

In a bid to sustain its growth trajectory, bioAffinity has expanded its physician network by 300%, significantly increasing the number of signed offices ready to utilize CyPath® Lung. Additionally, the inclusion of the test in the U.S. Federal Supply Schedule at over 1,380 government healthcare facilities ensures vital resources for high-risk populations, particularly veterans.

Supporting this growth are recent leadership appointments, with J. Michael Edwards stepping in as Chief Financial Officer and William Bauta as Chief Science Officer. Their expertise is expected to sharpen the company’s focus on furthering the commercialization of innovative diagnostic solutions.

With a solid operational foundation and a commitment to excellence, bioAffinity Technologies is poised to make lasting contributions to lung health, benefitting both patients and investors as it continues to navigate the expanding landscape of healthcare diagnostics.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.